两个专业协会最近发表了关于“马赛克”结果的临床管理的意见,该结果来自与体外受精(IVF)相关的人类囊胚期胚胎非整倍体(PGT-A)的植入前遗传测试。我们在这里指出三个主要缺点:(i)尽管最近的社会舆论指出,它不应被理解为对PGT-A使用的认可,任何关于PGT-A应如何在临床上解释所有实际目的的讨论都提供了这样的认可.(ii)同一指南的大部分意见来自先前的指南,以支持使用PGT-A,该指南甚至没有遵循建立实践指南的最低专业要求。(iii)关于两个社会的所谓“马赛克”胚胎的发布指南与人类植入前阶段胚胎的基本生物学特征相矛盾。They,此外,临床上未经验证并解释测试结果,越来越多的认为对许多不孕妇女的IVF结果有害。合格的专业组织,因此,最终应提供有关PGT-A与IVF联合使用的透明指南。
Two professional societies recently published opinions on the clinical management of \"mosaic\" results from preimplantation genetic testing for aneuploidy (PGT-A) in human blastocyst-stage embryos in associations with in vitro fertilization (IVF). We here point out three principal shortcomings: (i) Though a most recent societal opinion states that it should not be understood as an endorsement of the use of PGT-A, any discussion of how PGT-A should be clinically interpreted for all practical purposes does offer such an endorsement. (ii) The same
guideline derived much of its opinion from a preceding guidance in favor of utilization of PGT-A that did not follow even minimal professional requirements for establishment of practice
guidelines. (iii) Published
guidelines on so-called \"mosaic\" embryos from both societies contradict basic biological characteristics of human preimplantation-stage embryos. They, furthermore, are clinically unvalidated and interpret results of a test, increasingly seen as harmful to IVF outcomes for many infertile women. Qualified professional organizations, therefore, should finally offer transparent
guidelines about the utilization of PGT-A in association with IVF in general.